Viyash Scientific Limited
(Formerly known as Sequent Scientific Limited)
Registered Office:
3rd Floor, Srivalli's Corporate, Plot No.290, Road No.6,
Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills,
Hyderabad, Shaikpet, Telangana, India-500033
T: +91 40 23635000,
E: investorrelations@viyash.com
Website: www.viyash.com
CIN: L99999TS1985PLC196357

August 11, 2026

To,

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400 001	**National Stock Exchange of India Limited** Exchange Plaza, Bandra-Kurla Complex, Bandra (East), Mumbai - 400 051
Scrip code: 512529	**Symbol: VIYASH**

Dear Sir/ Madam,

Subject: Press Release for Q1 FY 2026-27

Dear Sir/Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Press Release on Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026.

This is for your information and appropriate dissemination.

Thanking you,

Yours faithfully,
For **Viyash Scientific Limited**
(Formerly known as Sequent Scientific Limited)

YOSHITA SUSMIT VORA

Digitally signed by YOSHITA SUSMIT VORA
Date: 2026.08.11 13:41:33 +05'30'

Yoshita Vora
Company Secretary & Compliance Officer

Viyash Scientific Limited
(Formerly known as Sequent Scientific Limited)
Registered Office: 3rd Floor, Srivalli's Corporate, Plot No.290, Road No.6, Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India-500033
T: +91 40 23635000, E:info@viyash.com
E: investorrelations@viyash.com
Website: www.viyash.com CIN: L99999TS1985PLC196357

Marching ahead on the integrated platform journey with robust growth

Q1 FY27 Performance Highlights

- **Revenues at ₹ 9,464 Million up by 19.5%** ↑
- **EBITDA* at ₹ 2,047 Million up 59.2 %** ↑
- **PAT at ₹ 793 Million, up by 114.9%** ↑
- **Net Debt / EBITDA* at 0.1 x** ↓

Hyderabad, August 11, 2026

Viyash Scientific Limited (formerly SeQuent Scientific Limited), which has businesses spread across Formulations, APIs and CDMO Services for Human and Animal health, today announced its financial results for the quarter ended June 30, 2026.

Consolidated Financial Highlights

₹ in millions

	Q1FY27	Q1FY26	Growth %
Revenues	9,464	7,916	19.5%
EBITDA*	2,047	1,286	59.2%
EBITDA* %	21.6%	16.2%	
PAT	793	369	114.9%

EBITDA* refers to EBITDA excluding ESOP costs

Detailed presentation on the performance forms part of this press release

Commenting on the Company's performance, **Dr Hari Babu Bodepudi, Managing Director and Group CEO** stated that

"Our performance in Q1 FY27 reflects the continued success of our integration efforts and the strength of the combined entity. This quarter's results are underpinned by robust execution, improving operating leverage, and a well-defined growth strategy. The acquisition of Bio For Life in Italy is a significant step in advancing our strategic focus on the companion animal segment, providing us with market access and a platform to launch our product portfolio in key European markets. As we move forward, our focus remains on disciplined execution, operational efficiency, and strategic investments in line with our long-term strategy for sustainable growth "

Earnings Call with Investors

The Company will conduct an Earnings call at **3:30 PM IST** on **August 12, 2026** where the Management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. The dial-in numbers for this call are **+91 22 6280 1263** or **+91 22 7115 8213**

About Viyash Scientific Limited

Viyash Scientific Limited (formerly known as Sequent Scientific Limited) headquartered in India is globally among top-25 Animal Health companies. With over 3,000 talented employees, Viyash Scientific Limited is an integrated pharmaceutical company having a rich portfolio of formulations and APIs for human and veterinary use, serving customers in 100+ countries. Viyash and its subsidiaries have manufacturing, R&D and distribution operations across India, Spain, Brazil, Turkey and USA, with approvals from international regulatory bodies, including USFDA, EUGMP, WHO, TGA, etc.

For details, feel free to contact

Yoshita Vora

Company Secretary, Tel: +91 22 4111 4717

investorrelations@viyash.com

Abhishek Singhal

Investor Relations Consultants

abhishek@arunya.co.in

Registered Office

3rd Floor, Srivalli's Corporate,

Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills,

Shaikpet, Hyderabad-500033, Telangana

CIN: L99999TS1985PLC196357

BSE Code: 512529 I NSE: VIYASH

ISIN: INE807F01027 I REUTERS: EQU.BO

Website: www.viyash.com